This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Company News For Jun 18, 2019
by Zacks Equity Research
Companies In The News Are: DISH,TMUS,S,ARRY,PFE,BID,BA
Big Ticket Mergers Are in Focus
by Zacks Equity Research
Big Ticket Mergers Are in Focus
"Merger Monday" Returns: Pfizer Buying Array, T-Mobile-Sprint on Ice?
by Mark Vickery
News on two major mergers in their respective industries are taking headlines, along with a fresh regional economic read.
Dow 30 Stock Roundup: United Technologies-Raytheon Merger, Merck's Tilos Buyout
by Swarup Gupta
The index traversed a volatile week, guided largely by trade-related developments.
Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti
by Zacks Equity Research
FDA approves Amgen (AMGN) and Allergan's Kanjiniti, a biosimilar version of Roche's (RHHBY) breast cancer drug, Herceptin.
Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study
by Zacks Equity Research
Pfizer's (PFE) study on JAK inhibitor Xeljanz XR demonstrates the efficacy of the medicine when used as a monotherapy without methotrexate.
Galapagos Ends Enrollment in Osteoarthritis Study Before Time
by Zacks Equity Research
Galapagos (GLPG) closes enrollment in the phase II study on GLPG1972/S201086 for the treatment of patients with osteoarthritis prior to the stipulated date.
Novartis Reports Data on Cosentyx for Psoriatic Arthritis
by Zacks Equity Research
Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $43.10, marking a +1.01% move from the previous day.
Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Boost Your Portfolio's Health With These 3 Big Drug Stocks
by Kinjel Shah
The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
Top Ranked Income Stocks to Buy for June 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, June 12th
TherapeuticsMD Enters Agreement to Market Drugs Outside US
by Zacks Equity Research
TherapeuticsMD (TXMD) grants exclusive commercialization rights to its drugs, Bijuva and Imvexxy, to Theramex in ex-U.S. markets except for Canada and Israel.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $42.76, marking a +0.66% move from the previous day.
Lilly's Emgality Gets FDA Approval for Cluster Headache
by Zacks Equity Research
Lilly's (LLY) CGRP antibody, Emgality, becomes the first and only medicine approved to treat episodic cluster headache in adults.
Zacks Market Edge Highlights: Pfizer, Vanguard S&P 500 ETF, Global X Social Media ETF, Kraneshares China Internet ETF and Microsoft
by Zacks Equity Research
Zacks Market Edge Highlights: Pfizer, Vanguard S&P 500 ETF, Global X Social Media ETF, Kraneshares China Internet ETF and Microsoft
Blueprint Medicines to File NDA for Avapritinib With FDA
by Zacks Equity Research
Blueprint Medicines' (BPMC) excessive confidence in partners for revenue recognition is still a huge cause for concern.
Top Tips for Long-Term Stock Investors
by Tracey Ryniec
The stock market is volatile again. Here's how to make it through the ups and downs.
The Zacks Analyst Blog Highlights: Pfizer, Coca-Cola, VMware, NIKE and AIG
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Coca-Cola, VMware, NIKE and AIG
Pfizer to Launch Several Drugs Despite Generic Headwinds
by Zacks Equity Research
Pfizer (PFE) looks well positioned to launch several breakthrough innovative medicines in the next five years amid loss of exclusivity headwinds.
Top Research Reports for Pfizer, Coca-Cola & VMware
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Coca-Cola (KO) and VMware (VMW).
Blueprint Medicines' NDA for Avapritinib on Track for GIST
by Zacks Equity Research
Blueprint Medicines (BPMC) reports data on avapritinib from NAVIGATOR study for treating patients with PDGFRA Exon 18 mutant GIST and the fourth-line GIST.
Merck's Keytruda Improves 5-Year Survival in Lung Cancer
by Zacks Equity Research
Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates
Dow 30 Stock Roundup: BA's Dreamliner Order, MSFT LinkedIn's Drawbridge Buyout Plan
by Swarup Gupta
The index endured another tough week as investors braced for an economic slowdown.
Pfizer (PFE) Up 2.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.